Russell Investments Group Ltd. Buys 117,508 Shares of TG Therapeutics, Inc. $TGTX

Key Points

• Russell Investments Group Ltd. increased its holdings in TG Therapeutics by 338.6% during Q1, owning over 152,000 shares valued at approximately $6 million.
• Goldman Sachs upgraded TG Therapeutics to a "hold" rating with a price target of $37.00, while the stock currently has an average rating of "Moderate Buy" and a target price of $46.25.
• TG Therapeutics reported a net loss with $0.17 EPS for the last quarter, missing the consensus estimate of $0.32, and had revenues of $141.15 million.

Russell Investments Group Ltd. lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 338.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 152,214 shares of the biopharmaceutical company's stock after acquiring an additional 117,508 shares during the quarter. Russell Investments Group Ltd. owned 0.10% of TG Therapeutics worth $6,002,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. CWM LLC increased its position in shares of TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after acquiring an additional 290 shares during the last quarter. Golden State Wealth Management LLC increased its position in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares during the last quarter. Xponance Inc. increased its position in shares of TG Therapeutics by 5.3% during the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after acquiring an additional 543 shares during the last quarter. Choreo LLC increased its position in shares of TG Therapeutics by 7.6% during the first quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 602 shares during the last quarter. Finally, NBC Securities Inc. increased its position in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the transaction, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.64% of the stock is owned by insiders.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.67 during trading hours on Friday, reaching $29.44. The stock had a trading volume of 2,182,164 shares, compared to its average volume of 2,885,902. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock has a 50 day simple moving average of $34.09 and a 200 day simple moving average of $35.71. TG Therapeutics, Inc. has a 12-month low of $21.11 and a 12-month high of $46.48. The stock has a market cap of $4.67 billion, a P/E ratio of 79.57 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. During the same period in the prior year, the business earned $0.04 earnings per share. The business's quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.